...
search icon
  • Apple, Inc AAPL
  • S&P 500 ETF Trust SPDR SPY
  • Alphabet Inc. - Class A Shares GOOGL
  • Microsoft Corporation MSFT
  • Meta Platforms Inc META
  • Netflix, Inc. NFLX
  • Amazon.com Inc. AMZN
  • Spotify Technology SA SPOT
    tlx-img

    Telix Pharmaceuticals Limited, Common Stock

    TLX

    NSQ

    $10.97

    -$0.33

    (-2.92%)

    1D

    Analyst Forecast

    Overview Returns Financials Ratios News FAQs

    Price Chart

    Key Metrics

    Market Cap info-icon
    This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
     $3.98B
    P/E Ratio info-icon
    This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
     173.4444
    Volume info-icon
    This is the total number of shares traded during the most recent trading day.
     78.97K
    Avg Volume info-icon
    This is the average number of shares traded during the most recent 30 days.
     0
    Dividend Yield info-icon
    This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
     0.00%
    Beta info-icon
    This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
     2.38
    52-week Range info-icon
    This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
    $10.7 L
    $30.36 H
    $10.97

    About Telix Pharmaceuticals Limited, Common Stock

    Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection). It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company was founded in 2015 and is headquartered in North Melbourne, Australia. more

    Returns

    Data is not properly formatted.

    Financials

    Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
    Total Revenue5.21M7.60M160.10M502.55M783.21M[{"date":"2020-12-31","value":0.67,"profit":true},{"date":"2021-12-31","value":0.97,"profit":true},{"date":"2022-12-31","value":20.44,"profit":true},{"date":"2023-12-31","value":64.17,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
    Cost of Revenue22.09M37.36M130.76M188.16M273.53M[{"date":"2020-12-31","value":8.08,"profit":true},{"date":"2021-12-31","value":13.66,"profit":true},{"date":"2022-12-31","value":47.8,"profit":true},{"date":"2023-12-31","value":68.79,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
    Gross Profit(16.88M)(29.77M)29.34M314.39M509.68M[{"date":"2020-12-31","value":-3.31,"profit":false},{"date":"2021-12-31","value":-5.84,"profit":false},{"date":"2022-12-31","value":5.76,"profit":true},{"date":"2023-12-31","value":61.68,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
    Gross Margin(323.75%)(391.85%)18.32%62.56%65.08%[{"date":"2020-12-31","value":-497.49,"profit":false},{"date":"2021-12-31","value":-602.15,"profit":false},{"date":"2022-12-31","value":28.16,"profit":true},{"date":"2023-12-31","value":96.13,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
    Operating Expenses32.38M51.48M102.52M263.27M427.55M[{"date":"2020-12-31","value":7.57,"profit":true},{"date":"2021-12-31","value":12.04,"profit":true},{"date":"2022-12-31","value":23.98,"profit":true},{"date":"2023-12-31","value":61.58,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
    Operating Income(49.25M)(81.25M)(73.18M)51.89M82.13M[{"date":"2020-12-31","value":-59.97,"profit":false},{"date":"2021-12-31","value":-98.92,"profit":false},{"date":"2022-12-31","value":-89.1,"profit":false},{"date":"2023-12-31","value":63.18,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
    Total Non-Operating Income/Expense(12.11M)(23.01M)(31.21M)(61.55M)(52.15M)[{"date":"2020-12-31","value":-1210800000,"profit":false},{"date":"2021-12-31","value":-2301000000,"profit":false},{"date":"2022-12-31","value":-3120800000,"profit":false},{"date":"2023-12-31","value":-6155300000,"profit":false},{"date":"2024-12-31","value":-5214800000,"profit":false}]
    Pre-Tax Income(60.25M)(99.04M)(98.62M)3.09M56.06M[{"date":"2020-12-31","value":-107.49,"profit":false},{"date":"2021-12-31","value":-176.68,"profit":false},{"date":"2022-12-31","value":-175.93,"profit":false},{"date":"2023-12-31","value":5.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
    Income Taxes(15.37M)(18.53M)5.46M(2.12M)6.14M[{"date":"2020-12-31","value":-250.38,"profit":false},{"date":"2021-12-31","value":-301.92,"profit":false},{"date":"2022-12-31","value":88.92,"profit":true},{"date":"2023-12-31","value":-34.61,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
    Income After Taxes(44.89M)(80.51M)(104.08M)5.21M49.92M[{"date":"2020-12-31","value":-89.92,"profit":false},{"date":"2021-12-31","value":-161.28,"profit":false},{"date":"2022-12-31","value":-208.5,"profit":false},{"date":"2023-12-31","value":10.44,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
    Income From Continuous Operations(44.89M)(80.51M)(104.08M)5.21M49.92M[{"date":"2020-12-31","value":-89.92,"profit":false},{"date":"2021-12-31","value":-161.28,"profit":false},{"date":"2022-12-31","value":-208.5,"profit":false},{"date":"2023-12-31","value":10.44,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
    Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
    Net Income(44.89M)(80.51M)(104.08M)5.21M49.92M[{"date":"2020-12-31","value":-89.92,"profit":false},{"date":"2021-12-31","value":-161.28,"profit":false},{"date":"2022-12-31","value":-208.5,"profit":false},{"date":"2023-12-31","value":10.44,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
    EPS (Diluted)----0.06[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]

    Ratios

    Liquidity

    These ratios help you determine the liquidity of the company. Higher is better.

    TLX
    Cash Ratio 2.15
    Current Ratio 2.78
    Quick Ratio 2.66

    Asset Efficiency

    These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

    TLX
    ROA (LTM) 7.97%
    ROE (LTM) 20.49%

    Liabilities

    These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

    TLX
    Debt Ratio Lower is generally better. Negative is bad. 0.63
    Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.37

    Valuation

    These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

    TLX
    Trailing PE 173.44
    Forward PE 77.52
    P/S (TTM) 8.09
    P/B 20.71
    Price/FCF NM
    EV/R 12.96
    EV/Ebitda 113.13

    Discover more

    Tsla

    Tesla, Inc.
    aaple

    Apple, Inc.
    GOOGL

    Alphabet Inc. - Class A Shares
    META

    Meta Platforms Inc
    AMZN

    Amazon.com Inc.
    Microsoft

    Microsoft Corporation
    NVDA

    NVIDIA Corporation
    BRK

    Berkshire Hathaway Inc. Hld B
    LLY

    Eli Lilly and Company

    FAQs

    What is Telix Pharmaceuticals Limited share price today?

    Telix Pharmaceuticals Limited (TLX) share price today is $10.97

    Can Indians buy Telix Pharmaceuticals Limited shares?

    Yes, Indians can buy shares of Telix Pharmaceuticals Limited (TLX) on Vested. To buy Telix Pharmaceuticals Limited from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TLX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

    Can Fractional shares of Telix Pharmaceuticals Limited be purchased?

    Yes, you can purchase fractional shares of Telix Pharmaceuticals Limited (TLX) via the Vested app. You can start investing in Telix Pharmaceuticals Limited (TLX) with a minimum investment of $1.

    How to invest in Telix Pharmaceuticals Limited shares from India?

    You can invest in shares of Telix Pharmaceuticals Limited (TLX) via Vested in three simple steps:

    • Click on Sign Up or Invest in TLX stock at the top of this page
    • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
    • Transfer USD funds to your US Brokerage account and start investing in Telix Pharmaceuticals Limited shares
    What is Telix Pharmaceuticals Limited 52-week high and low stock price?

    The 52-week high price of Telix Pharmaceuticals Limited (TLX) is $30.36. The 52-week low price of Telix Pharmaceuticals Limited (TLX) is $10.7.

    What is Telix Pharmaceuticals Limited price-to-earnings (P/E) ratio?

    The price-to-earnings (P/E) ratio of Telix Pharmaceuticals Limited (TLX) is 173.4444

    What is Telix Pharmaceuticals Limited price-to-book (P/B) ratio?

    The price-to-book (P/B) ratio of Telix Pharmaceuticals Limited (TLX) is 20.71

    What is the Market Cap of Telix Pharmaceuticals Limited?

    The market capitalization of Telix Pharmaceuticals Limited (TLX) is $3.98B

    What is Telix Pharmaceuticals Limited’s stock symbol?

    The stock symbol (or ticker) of Telix Pharmaceuticals Limited is TLX

    Feedback

    Signup to access all features and start your US investing journey!

    • Open your account in minutes
    • Take your portfolio global, starting at just $1
    Get started

    Add ticker to compare

    Scroll to Top